Carcinoma of the cervix by Resbeut, M et al.
Cervical cancer is the second most common cancer in women. In
France, the standardized incidence in 1990 was 9.4 per 100 000.
Uncommon under the age of 30, the incidence increases progres-
sively thereafter to around 50 per 100 000 between the ages of 50
and 70 years. The standardized death rate is 3.5 per 100 000 in
France and 3.9 per 100 00 in Europe. 
This document covers the diagnostic and therapeutic manage-
ment of microinvasive and invasive carcinomas of the cervix and
excludes the screening or management of cervical intraepithelial
neoplasia. 
These guidelines were validated in July 1997 and will be
updated according to the publication of new data. 
COLPOSCOPY 
The reproducibility of colposcopy is poor and the inter- and intra-
operator variability is high. The overall sensitivity and specificity
of the examination is limited. The diagnosis is unreliable if the
superior limit of the lesion cannot be seen, in which case endocer-
vical curettage should be added to confirm the diagnosis (option).
Because of its very poor specificity, endocervical curettage is not
of value when colposcopy is satisfactory (assuming the junctional
zone is seen). Colposcopy following an abnormal smear should
facilitate targeted biopsies. These must be interpreted with
caution, especially when destructive treatment is to follow (laser
or cryotherapy) and the biopsy lesion is high-grade. 
PRETHERAPEUTIC ASSESSMENT 
This must be carried out by a multidisciplinary team, which
includes a specialist surgeon and a radiotherapist, irrespective of
the stage of disease. An examination under general anaesthetic is
optional. Cystoscopy is indicated for large-volume tumours and/or
those with anterior extension (option). Rectoscopy and subsequent
endorectal ultrasonography is only indicated if rectal invasion is
suspected (option). 
Visualization of the urinary tract is standard, using intravenous
urography, renal and bladder ultrasonography, CT scanning or
MRI (options). Local extension can be assessed by supra-pubic
and vaginal ultrasonography or MRI (options). For proximal
tumours less than or equal to stage IIB, local assessment is
optional. In the absence of surgical verification, nodal extension
can be assessed by CT scan, MRI or lymphography (options).
There is no consensus as to which investigations should be carried
out to exclude the presence of metastatic disease. 
Tumour markers are not of diagnostic value. The measurement
of squamous cell carcinoma antigen and of CA125 in the case of
adenocarcinoma is recommended at diagnosis in order to obtain a
baseline reference value. They can then be used as markers when
assessing efficacy of treatment and/or progression of disease.
There is no indication to measure both markers routinely (stan-
dard). Currently, there is no indication for human papillomavirus
typing (standard); this should only be done in the context of a trial. 
CLASSIFICATION 
The following classifications may be used (options): 
l classification of the International Federation of Gynaecologists
and Obstetricians (FIGO) 
l TNM classification 
l classification of the MD Anderson Cancer Center 
l classification of the Institute Gustave Roussy. 
These are all based on the local extent of tumour. The classifica-
tion used most often is that of FIGO. This distinguishes limited
forms (IA, IIA, IIB) and advanced forms of disease (III, IV).
Within stage IIB, those with invasion proximal to the parametrium
are considered as limited disease and the others as advanced
disesase. In order that the results of different therapies can be
compared, it is recommended that the FIGO classification is
always used either alone or combined with another classification
system. 
DIAGNOSIS 
The histopathological examination of a surgical biopsy specimen
(cone biopsy or hysterectomy) that includes the entire abnormal
lesion is necessary for the diagnosis of a microinvasive carcinoma. 
The histological evaluation of microinvasive carcinomas must
document the (standard): 
l positive diagnosis of an invasive malpighian carcinoma of
limited stage 
l maximum depth of tumour infiltration measured in millimetres 
l degree of lateral extension of any infiltrating lesions measured
in millimetres 
l presence of vascular involvement 
l quality of the surgical margins. 
The histopathological evaluation of invasive carcinomas must
include the (standard): 
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l confirmation of invasive cancer 
l histological classification 
l determination of the associated morphological risk-factors. 
PROGNOSTIC FACTORS 
Independent prognostic factors are the tumour volume (for limited
disease only) and the FIGO stage. The latter is correlated with
local control in the pelvis, survival and the development of metas-
tases. The prognostic value of tumour volume is limited for locally
advanced disease with parametrial extension (uni- or bi-
lateral) and for distal extension (level of evidence C). Lymphatic
invasion is an independent prognostic factor for disease limited to
the cervix. The number of nodes, the upper level of invasion and
bilateral involvement are also of prognostic value. 
THERAPEUTIC MODALITIES 
Surgery 
Staging at the time of initial surgery is standard, although if radio-
therapy is to be the primary or only treatment, surgical exploration
is optional. Staging includes exploration of the abdomen and
lymphadenectomy (standard). Peritoneal cytology is optional and
is only of value if it modifies subsequent therapy. Pelvic lymph-
adenectomy can be by laparotomy, by a retroperitoneal approach
or by laporoscopy. Laparoscopic lymphadenectomy is only recom-
mended if the operator has specific training in this technique.
Lymphadenectomy in limited disease must include the external
iliac nodes (level of evidence B). A more extensive lymphadenec-
tomy in limited-stage disease should only be done within a trial
setting. 
In stage IIB disease, lymphadenectomy should be extended to
the level of the renal artery before the primary tumour is excised.
When the uterus is not resected, lymphadenectomy should be
carried out via a retroperitoneal approach or by laparoscopy.
Lymphadenectomy enables precise pretherapeutic staging of nodal
involvement in order to define the extent of the radiotherapy fields
necessary for treatment. The retroperitoneal route results in fewer
postoperative complications related to the development of
adhesions. 
Ovarian transposition is also possible by laparoscopy (level of
evidence B). Total hysterectomy can be by laparotomy or via the
vaginal route (option). A median laparotomy is recommended for
hysterectomy if the operator has no specific training in other tech-
niques. When the ovaries are to be conserved, they must be
marked with radio-opaque labels at the time of laparotomy or lapa-
roscopy (standard). Pelvic shielding is recommended when post-
opertive radiotherapy is to be given. The surgeon must describe
the type of uterine excision undertaken (standard) and use the clas-
sification of Piver. 
Radiotherapy 
There are several techniques for endocavitary brachytherapy,
including the standard system and techniques using moulds 
(option). Parametrial interstitial brachytherapy must only be given
within a trial. Standard dosimetry is that according to the recom-
mendations of the International Commission of Radiation Units.
There is no survival advantage associated with high-dose rate
compared to low dose rate delivery (level of evidence C).
Brachytherapy at a low dose rate remains the standard (level of
evidence C). 
External radiotherapy uses photon energy equal or superior to
10 MV (standard). The use of simulation is standard. Pelvic radio-
therapy should include at least two fields (standard), and the use of
four fields is recommended (level of evidence C). The upper limit
of the pelvic area is situated at the L4–L5 junction (standard). For
low-volume stage IB–IIA disease, in the absence of nodal involve-
ment, this limit can be reset at the level of L5–SI (option). The
inferior limit depends on whether or not the vagina is involved. In
all cases, the minimal safe margin is 4 cm below the lowest tumour
level (standard). In the case of tumour extension to the lower
vagina or of infiltration distal to the parametrium, radiotherapy
must include the whole vagina (standard). The lateral limit of the
antero-posterior field must always cover the nodal zones (stan-
dard). If the vagina is involved, prophylactic inguinal radiotherapy
can be incorporated (option). Conformational radiotherapy, hyper-
thermia, neutron therapy, hyperbaric oxygen and radiosensitizers
remain as research tools and must be used within therapeutic trials. 
The most important factors in radiotherapy of cervical cancer
are the volume irradiated, the total dose of irradiation and its dura-
tion. The sequencing of external radiotherapy and brachytherapy
in radiobrachytherapy combinations has not been shown to effect
results (level of evidence C). There are two options: initial external
radiotherapy to the total pelvis at a minimum dose of 40 Gy
followed by brachytherapy; and external radiotherapy at a lower
dose preceding brachytherapy followed by a latero-pelvic boost. 
For limited-stage disease, the combination of external radio-
therapy/brachytherapy must deliver a total dose of 60 Gy to the
central pelvis (specified by the reference isodose) and 45–50 Gy to
the lateral pelvic area (standard, level of evidence C). For locally
advanced disease, with distal invasion of the parametrium or meta-
static pelvic nodes, a minimum of 55 Gy can be given to the pelvis
(standard) with the possibility of a boost up to 65–70 Gy within
very limited areas (option, level of evidence C). The central pelvic
dose is also 60 Gy (as specified by the reference isodose). 
The benefit of prophylactic radiotherapy to the para-aortic
region (option) has not been clearly established (level of evidence
C) and the risk of complications, in particular to the bowel, is
greatly increased (level of evidence B). Prophylactic radiotherapy
is delivered at a dose of 45 Gy (standard). For proven metastatic
spread (at the para-aortic level in the absence of metastases else-
where), para-aortic radiotherapy is standard, although the optimal
dose remains to be determined. 
Postoperative adjuvant radiotherapy, in the case of nodal
involvement or involvement of surgical excision margins, has not
been shown to be of benefit in terms of survival (level of evidence
C). There is a benefit in terms of a reduction in the risk of local
recurrence (level of evidence C). A variety of protocols are used
and these patients should be included in therapeutic trials. 
There is no evidence that modification of fractionation or
schedule of radiotherapy is beneficial in this disease (level of
evidence C); it should not be done outside a therapeutic trial. 
Radiochemotherapy 
Concomitant administration of cisplatin with radiotherapy signifi-
cantly improves local control (level of evidence A) and overall
survival (level of proof B) compared with radiotherapy alone or
the combination of radiotherapy and hydroxyurea. This applies to
patients with poor prognosis stage IB, IIA and IIB disease 26 M Resbeut et al
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(tumours greater than 4 cm and/or invasion of pelvic nodes and/or
microscopic invasion of the parametrium) and to stage III and IVA
disease. None of the patients included in these trials had para-
aortic nodal involvement. Radiochemotherapy should be consid-
ered as standard treatment for these stages although the benefit
seems to be less clear for patients with stage III and IVA disease
(level of evidence C) and must be confirmed. The chemotherapy
usually involves regimens based on cisplatin either alone or
combined with 5FU. 
The optimum drug scheduling has not been determined. Some
regimens involve weekly cisplatin at a dose of 40 mg m–2 and
others contain doses of 50–75 mg m–2 given every 3–4 weeks.
New randomized trials should clarify what is the best schedule of
chemotherapy in association with external radiotherapy or brachy
therapy. The toxicity of the combination of cisplatin, 5FU brachy
hydroxyurea is greater than for cisplatin alone with no greater effi-
cacy (level of evidence B). 
Chemotherapy 
Comparative trials of polychemotherapy and monotherapy have
shown a non-significant increase in early response rate for poly-
chemotherapy (level of evidence C). There is no evidence to
support the use of adjuvant chemotherapy (given after surgery
with or without radiotherapy) in terms of overall or relapse-free
survival for patients with unfavourable prognostic factors (level of
evidence C). Studies of new cytotoxics given in more efficacious,
less toxic combinations are required. Intra-arterial chemotherapy
remains experimental. Biological response modifiers remain
within the domain of clinical research. 
Treatment toxicity 
Prospective and regular long-term follow-up is recommended. The
evaluation of toxicity is standard. The best system for grading
treatment complications in cancer of the cervix is the Franco-
Italian system of Chassagne. 
The extent of surgery should not be deliberately limited in order
to reduce complications unless absolutely necessary. If the true
extent of disease could be determined pre-or perioperatively by
new imaging techniques or by laparoscopy, surgery could be indi-
vidualized, thus reducing morbidity. In this way, aggressive
surgery could be limited to cases of proven extensive disease.
Complications following laparoscopic surgery are less frequent,
but specific training is necessary for its use. 
The principle complications following treatment of cervical
cancer involve the bowel and urinary tract. If the factors primarily
responsible for radiotherapy-induced toxicity were known (e.g.
total dose, volume of irradiation, photon energy, dose to critical
organs, techniques of brachytherapy) the associated complications
could be limited. 
External para-aortic radiotherapy post-surgery increases the risk
of gut toxicity. To limit the complications of combined radio-
therapy and surgery, brachytherapy must be adapted to the surgery,
and vice-versa. The dose-limiting tolerance of critical organs must
be known, as stated in the recommendations of the International
Commission on Radiation Units. 
The toxicity of radiochemotherapy is predominantly haemato-
logical and intestinal (level of evidence B) and is greater than that
of radiotherapy alone (level of evidence B). The use of chemo-
therapy may add to the transient side-effects of locoregional 
treatment in operable cancers, but should not compromise the
results of surgery and contributes little to postoperative complica-
tions (level of evidence C). Induction or neoadjuvant chemo-
therapy before radiotherapy increases radiotherapy-induced toxicity
and the risk of treatment disruption/interruption, but does not
usually prevent the delivery of the planned dose (level of evidence
C). It is only indicated within prospective controlled trials.
THERAPEUTIC STRATEGY 
Stage IA disease 
Surgery is standard treatment (level of evidence B). Cone biopsy
(conization) or excision (amputation) of the cervix by the vaginal
route necessary for diagnosis (Figure 1), is sufficient for treatment
of stage IA1 disease up to 1 mm in depth (Figure 2) and from 1–
3 mm (Figure 3) in the absence of bad prognostic factors (level of
evidence B). If conization is to be the definitive treatment, it must
be complete (standard). Conization is recommended principally
for those women wishing to maintain fertility and who accept the
Treatment of
IA1 disease
< 1 mm
see Figure 2
Treatment of
IA1 disease
1-3 mm, see
Figure 3
Treatment of IA2
disease
see Figure 4
Penetration less than 1 mm?
Stage IA1
penetration < 3mm
Stage IA2
penetration 3 - 5 mm
Conization (not diagnostic) +
histopathological examination
MICROINVASIVE CARCINOMA
STAGE IA
yes no
Figure 1 Management of microinvasive carcinoma of the cervix (stage IA) 
Follow-up
Follow-up Follow-up
Standard
there is no standard
Options
according to localization:
· further surgery
· ablation
· follow-up
Standard
there is no standard
Options
· ablation
· further surgery
Residual exocervical
disease
Complete excision by cone biopsy
MICROINVASIVE CARCINOMA FOLLOWING CONE
BIOPSY
STAGE IA < 1mm
Residual endocervical
disease
yes no
Figure 2 Treatment of microinvasive disease (stage IA1, < 1 mm) Carcinoma of the cervix 27
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necessity for regular follow-up. A hysterectomy (Piver type I) is
the other therapeutic option. 
Whatever the depth of disease infiltration, the significance of
lymphatic emboli as an independent prognostic factor has not been
established. For disease of more than 3 mm (Figure 3), certain
groups, notably the North Americans, exclude lesions with
lymphatic emboli from the microinvasive category and treat them
as small-stage IB1 disease. External and interiliac lymphaden-
ectomy is recommended in the presence of lymphatic emboli. A
simple or a total (Piver type II) hysterectomy are options. For
disease greater than 3 mm in depth (Figure 4), (stage IA2),
whether or not there are bad prognostic factors, hysterectomy is
recommended. Most physicians treat these as stage IB1 disease. 
If there are lymphatic emboli, a total hysterectomy of Piver 
type II should be undertaken with external and interiliac lymph-
adenectomy. 
Stages IB, IIA, IIB good prognosis proximal disease 
This refers to N0 tumours of less than 4 cm in size with no micro-
scopic parametrial invasion, that have been treated surgically
(Figure 5). 
There is no difference in efficacy between surgery alone 
(Figure 6), radiotherapy alone and the combination of radio-
therapy and surgery (Figure 8), irrespective of whether the tumour
size is greater or less than 4 cm (level of evidence C) (Figure 5).
Radiotherapy alone includes external pelvic irradiation and
brachytherapy (Figure 7). Two applications of brachytherapy are
given with or without a boost. Hysterectomy after a minimum
delay of 8 weeks is recommended if there has been a poor response
to radiotherapy, especially for tumours greater than 4 cm in size 
(option, level of evidence C) (Figures 7 and 9). The respective
contributions of external radiotherapy (delivered to the whole
Standard
concomitant pelvic
radiochemotherapy
Options
· pelvic and para-
  aortic radiotherapy
· chemotherapy within 
  a trial
MICROINVASIVE CARCINOMA DIAGNOSED
FROM CONE BIOSPY
STAGE IA 1
1-3 mm
Lymphatic emboli
within cone biopsy?
yes no
Standard
surgery
Options
· simple hysterectomy
· total hysterectomy
· brachytherapy if surgery is
  contra-indicated
Option
lymphadenectomy
Exception
Option
complete excision by cone biopsy (if 
patient wishes to become pregnant)
Standard
surgery
Options
· complete excision cone biopsy
· simple hysterectomy ± excision
· cervical excision via the vagina
· brachytherapy (if surgery is 
  contra-indicated)
Has a 
lymphadenectomy
been carried out?
Yes
Yes
no
no Pelvic lymph nodes
involved?
Follow-up
Follow-up
Follow-up
Follow-up
Figure 3 Treatment of micro-invasive disease (stage IA1, 1–3 mm) pelvis) and of brachytherapy (in combination with radiosurgery),
depends on the size of the tumour as well as anatomic factors and
the general state of the patient. The size of the dose delivered by
external irradiation as compared to brachytherapy, increases with
the tumour volume. When there are appropriate anatomical and
clinical conditions, brachytherapy can be the sole radiotherapy
treatment for tumours less than 4 cm (Figure 8). In this case,
external radiotherapy is directed exclusively to the lateral pelvic
regions. 
Stages IB, IIA, IIB bad prognosis proximal disease 
This includes tumours greater or equal to 4 cm in size with or
without invasion of pelvic nodes but without involvement of para-
aortic nodes (Figure 9). Treatment can be either surgery or radio-
therapy. For patients treated by primary radiotherapy, the standard
is combination radiochemotherapy incorporating cisplatin. The
options are: cisplatin 40 mg m–2 per week or a cisplatin/5FU
combination with 50–75 mg m–2 cisplatin every 3–4 weeks and
4g  m –2 FU over 4 days. There is a significant improvement in
local control (level of evidence A) and overall survival (level of
evidence B) following cisplatin-based combination radiochemo-
therapy as compared to radiotherapy alone or the association of
radiotherapy and hydroxyurea. 
The toxicity of radiochemotherapy is essentially that of bone
marrow and gut toxicity (level of evidence B); it is greater than
that associated with radiotherapy alone (level of evidence B). The
best schedules of delivery of the chemotherapy have not been
established. In some studies the cisplatin was given weekly at a
dose of 40 mg m–2 and in others at doses between 50 and
75 mg m–2 every 3–4 weeks. Future randomized studies are likely
to establish the optimal dose of chemotherapy to be given in
combination with external radiotherapy and brachytherapy.
Although of equivalent benefit, the toxicity of a cisplatin/
5-FU/hydroxyurea combination is greater than that of cisplatin
alone (level of evidence B).
A hysterectomy (option) after a minimal delay of 8 weeks is
recommended in cases of poor response to chemotherapy, espe-
cially for tumours more than 4 cm in size (level of evidence C). 
For tumours greater than 4 cm, external-beam radiotherapy is
delivered first line to the whole pelvis before undertaking brachy-
therapy, with a boost to a total dose of 60 Gy to the lateral-pelvic
28 M Resbeut et al
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MICROINVASIVE CARCINOMA DIAGNOSED
FROM CONE BIOPSY
STAGE IA2
PENETRATION 3 - 5 mm
Standard
surgery
Options
·  simple hysterectomy
·  total hysterectomy (Piver II)
Options
Iymphadenectomy
Special cases
Options
·  complete excision by cone biopsy (for patients
   wishing to maintain fertility)
·  brachytherapy (if surgery is contraindicated)
Lymphadenectomy?
Pelvic lymph nodes
involved?
Standard
concomitant pelvic radio-
chemotherapy
Options
· pelvic and para-aortic radiotherapy
· chemotherapy (within a trial)
Follow-up
Follow-up
Follow-up
yes
yes no
no
Figure 4 Treatment of microinvasive disease (stage IA2, penetration
3–5 mm) 
Stages IB, IIA and IIB
proximal disease
primary surgery
size < 4 cm
see Figure 6
Stages IB, IIA and IIB
proximal disease
primary radiotherapy
size < 4 cm
see Figure 7
Stages IB, IIA and IIB
proximal disease
Combination radiosurgery
size < 4 cm
see Figure 8
Standard
there is no standard
Options
·  primary surgery
·  radiotherapy and brachytherapy
·  combination radiosurgery
TUMOUR SIZE < 4 cm
·  STAGE IB
·  STAGES IIA, IIB proximal disease
Figure 5 Management of invasive carcinoma < 4 cm (stage IB and stages
IIA, IIB proximal disease) 
TUMOUR SIZE < 4 cm
· STAGE IB
· STAGES IIA, IIB proximal disease
TREATMENT BY PRIMARY SURGERY
Standards
·  stage IB = Piver II or III
·  stages IIA or IIB = Piver III or IV
·  pelvic lymphadenectomy
Options
para-aortic lymphadenectomy
  
Clear excision margins
and no lymphatic
metastases
Standard
concomitant radiochemotherapy
Options
in the case of para-aortic nodes:
· para-aortic irradiation
· adjuvant chemotherapy within a trial
Follow-up Follow-up
yes no
Figure 6 Primary surgery of invasive carcinoma < 4 cm (stage IB and
stages IIA, IIB proximal disease) Carcinoma of the cervix 29
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region. Radiotherapy includes both external-beam irradiation and
brachytherapy. It is recommended that the total time taken to
deliver the radiotherapy (external-beam plus brachytherapy) is less
than 8 weeks. The respective contribution of the external-beam
pelvic radiotherapy and the brachytherapy depends on the size of
the tumour and various anatomic considerations. The size of the
dose delivered by external beam as compared to brachytherapy
increases with tumour size. Elderly patients or those with poor
performance status can be treated with radiotherapy alone. 
Stage IIB distal, stage III and IV disease 
For disease beyond stage IIB with invasion distal to the parame-
trium, radiotherapy, either as external beam or brachytherapy, can
be considered as standard treatment  (Figure 10) (level of evidence
C). The evidence comes from retrospective studies of patients
treated with radiotherapy alone. The benefit of prophylactic para-
aortic radiotherapy (option) has not been established (level of
evidence C) and carries an increased risk of complications (level of
evidence B). Para-aortic radiotherapy is standard treatment for
proven para-aortic nodal disease in the absence of metastases else-
where. In patients without involvement of para-aortic nodes, the
combination of cisplatin-based radiochemotherapy leads to
improved survival as compared to radiotherapy alone or the combi-
nation of radiotherapy and hydroxyurea (level of evidence B). This
benefit is less marked for stages III and IVA disease (level of
evidence C) and must be confirmed. These results have been
obtained with combination chemotherapy based on cisplatin, used
alone or in combination with 5-FU, but it does not appear that the
combination with 5-FU gives better results than cisplatin alone
(level of evidence C). The best schemes of administration of the
chemotherapy remain to be established. New randomized studies
are required looking as much at feasability (which is more limited
in advanced forms) as toxicity of the radiochemotherapy. Pelvic
exenteration is an option for stage IVA disease associated with
radiotherapy and/or preoperative chemotherapy (level of evidence
C). This option can be considered especially when there is no para-
metrial invasion, fixation to the pelvic wall, or para-aortic exten-
sion of disease. Surgery for other advanced stages (IIIB, III), with
or without preoperative radiotherapy, is not recommended outside
prospective therapeutic trials. 
TUMOUR SIZE < 4 cm
·  STAGE IB
·  STAGE IIA, IIB proximal disease
TREATMENT BY RADIOTHERAPY AND BRACHYTHERAPY
Standard
external radiotherapy and brachytherapy
Option
hysterectomy after a delay of at least 6 - 8 weeks
Residual tumour following
radiotherapy
Follow-up Follow-up
yes no
Figure 7 Radiotherapy of invasive carcinoma < 4 cm (stage IB and stages
IIA, IIB proximal disease) 
TUMOUR  SIZE < 4 cm
·  STAGE IB
·  STAGES IIA, IIB proximal disease
TREATMENT BY COMBINATION RADIOSURGERY
Standards
·  branchytherapy(± previous radiotherapy)
·  surgery: Piver II or III ± lymphadenectomy
Lymph node
involvement?
Standard
concomitant pelvic radiochemotherapy
Options
·  para-aortic irradiation
·  adjuvant chemotherapy within a trial
Follow-up Follow-up
yes no
Figure 8 Combined radiotherapy of invasive carcinoma < 4 cm (stage IB
and stages IIA, IIB proximal disease) 
Standard
concominant radiochemotherapy (external radiotherapy + brachytherapy)
Option
hysterectomy after a delay of at least 6 to 8 weeks
TUMOUR SIZE ³ 4 cm:
·  para-aortic nodes not involved
·  STAGE IB
·  STAGES IIA, IIB proximal disease
Follow-up
Figure 9 Treatment of invasive carcinoma ³ 4 cm without para-aortic node
involvement (stage IB and stages IIA, IIB proximal disease) 
Standards
·  concomitant radiochemotherapy (external radiochemotherapy + brachytherapy)
·  para-aortic irradiation if para-aoratic nodes involved
Options
·  if para-aortic nodes not involved: prophylatic para-aortic irradiation
·  stage IVA: pelvic exenteration
· STAGE IIB DISTAL
· STAGE III
· STAGE IVA
Follow-up
Figure 10 Treatment of stages IIB distal, III and IV disease 30 M Resbeut et al
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CANCER OF THE POST-HYSTERECTOMY
CERVIX 
The principle of treatment of these forms is identical to those for
cancers of the cervix with an intact uterus (level of evidence C). 
CANCER OF THE CERVIX IN PREGNANCY 
The recommendations for treatment are based on small series of
patients. A decision to treat immediately or to defer treatment
should take into consideration the stage of the tumour and the
maturity of the foetus but must not compromise the chances of
cure for the mother. The mother must be fully informed by a multi-
disciplinary team and be actively involved in the decision-making
process. Stage IA disease can be followed until the end of the preg-
nancy. For invasive cancers, priority should be given to the treat-
ment of the cancer during the first trimester of pregnancy. After the
second trimester, the attitude towards treatment varies. Close
surveillance is necessary throughout the pregnancy and treatment
is reconsidered according to whether or not the tumour is
progressing. The results of treatment do not appear to be affected
by the state of pregnancy. As these are generally young patients,
preference is often given to surgery, although there is no clear
evidence to support this choice. 
FOLLOW-UP 
Regular surveillance of cervical cancer after initial treatment is
justified because of the possibility of treating pelvic and/or vaginal
recurrence (level of evidence C). This involves history-taking and
clinical examination (standard). A search for treatment-related
complications should be routine (standard). The ideal frequency of
follow-up has not been evaluated. The recommendations are: three
to four times per year during the first 2 years, then every 6 months
for the following 3 years then once a year. 
The place of vaginal smears (option) in the follow-up has not
been clearly established. Routine smears add nothing to clinical
examination with respect to the detection of recurrence (level of
evidence C) and should only be done if clinically indicated. The
value of routine imaging and/or marker assays has not been
demonstrated; they should only be undertaken according to
clinical signs. 
Hormone replacement therapy is not contra-indicated but one
should be cautious with adenocarcinomas. 
PSYCHOSEXUAL ISSUES 
Two thirds of patients treated for cancer of the cervix will experi-
ence psychological and sexual problems that are likely to interfere
with their relationships. The prevention of sexual difficulties relies
on taking precautions with respect to treatment techniques, in
order to limit subsequent organic and functional problems, as well
as caring for the patient’s psychological welfare. As for predict-
able sexual problems, the aim is to try to maintain a close and
harmonious relationship between the couple. Each case must be
considered individually and the exact needs of the patient consid-
ered (if possible in the presence of her partner), to select an indi-
vidualized and therefore more effective management. 
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